Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients
Copyright © 2023. Published by Elsevier Inc..
Immunotherapy is currently approved for CRC whose tumors have high MSI-H. To find additional biomarkers for immunotherapy in CRC, targeted sequencing was performed on tumor tissues from a discovery cohort of 161 CRC patients. Validation cohorts from the cBioPortal were also used for survival and tumor cell infiltration analyses. The FAT1-mutated CRC group often co-occurred with MSI events and displayed a higher tumor mutational burden compared to the FAT1 wild-type CRC. Overall survival was higher in patients with FAT1 mutations than in patients with wild type FAT1. The altered PI3K-AKT pathway and immune pathways were enriched in the FAT1-mutated CRC. A higher infiltration rate of immune cells including CD4+ T cells, CD8+ T cells, macrophages M1 and regulatory T cells were also observed in the colorectal tumors with FAT1 mutation compared to tumors with wild type FAT1. The results showed that CRC patients with FAT1 mutations exhibited an immunotherapy-favorable profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Genomics - 116(2024), 2 vom: 01. März, Seite 110808 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cadherins |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ygeno.2024.110808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368550435 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368550435 | ||
| 003 | DE-627 | ||
| 005 | 20240323000808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygeno.2024.110808 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM368550435 | ||
| 035 | |a (NLM)38364976 | ||
| 035 | |a (PII)S0888-7543(24)00029-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Immunotherapy is currently approved for CRC whose tumors have high MSI-H. To find additional biomarkers for immunotherapy in CRC, targeted sequencing was performed on tumor tissues from a discovery cohort of 161 CRC patients. Validation cohorts from the cBioPortal were also used for survival and tumor cell infiltration analyses. The FAT1-mutated CRC group often co-occurred with MSI events and displayed a higher tumor mutational burden compared to the FAT1 wild-type CRC. Overall survival was higher in patients with FAT1 mutations than in patients with wild type FAT1. The altered PI3K-AKT pathway and immune pathways were enriched in the FAT1-mutated CRC. A higher infiltration rate of immune cells including CD4+ T cells, CD8+ T cells, macrophages M1 and regulatory T cells were also observed in the colorectal tumors with FAT1 mutation compared to tumors with wild type FAT1. The results showed that CRC patients with FAT1 mutations exhibited an immunotherapy-favorable profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a FAT1 | |
| 650 | 4 | |a Immune cell infiltration | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a MSI | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a FAT1 protein, human |2 NLM | |
| 650 | 7 | |a Cadherins |2 NLM | |
| 700 | 1 | |a Yang, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yuqian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Kaihua |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ruoying |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wentong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Guosheng |e verfasserin |4 aut | |
| 700 | 1 | |a He, Junjun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genomics |d 1990 |g 116(2024), 2 vom: 01. März, Seite 110808 |w (DE-627)NLM012628867 |x 1089-8646 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2024 |g number:2 |g day:01 |g month:03 |g pages:110808 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygeno.2024.110808 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2024 |e 2 |b 01 |c 03 |h 110808 | ||